Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
Introduction: The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, real-world data are still missing. Objectives: To provide evidence about effectiveness and safety of tofacitinib and baricitinib in AA in real-world settin...
Saved in:
Main Authors: | Zoe Apalla (Author), Efterpi Zafiriou (Author), Effimia Zagkliverinou (Author), Angeliki-Viktoria Ro (Author), Polyxeni Gidarokosta (Author), Niki Ntavari (Author), Stella Sakellaropoulou (Author), Maria Boziou (Author), Anastasia Emvalomati (Author), Eirini Kyrmanidou (Author), Elizabeth Lazaridou (Author) |
---|---|
Format: | Book |
Published: |
Mattioli1885,
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Patch testing in patients with alopecia areata: a case-series study
by: Eirini Kyrmanidou, et al.
Published: (2022) -
Which is the ideal JAK inhibitor for alopecia areata - Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
by: Kabir Sardana, et al.
Published: (2023) -
Alopecia areata treatment with baricitinib: different relapse phenotypes
by: Federica Dall'Oglio, et al.
Published: (2024) -
Transient Efficacy of Tofacitinib in Alopecia Areata Universalis
by: Florian Anzengruber, et al.
Published: (2016) -
Non-Melanoma Skin Cancer and Vitamin D: The "Lost Sunlight" Paradox and the Oxidative Stress Explanation
by: Emmanouil Karampinis, et al.
Published: (2023)